Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
about
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experienceLimiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftmentMobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Chemokines as therapeutic targets for atherosclerotic plaque destabilization and rupture.Peripheral blood stem cell mobilization tactics.Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.Novel strategies for blood stem cell mobilization: special focus on plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Advances in stem cell mobilization.Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Plerixafor for autologous CD34 cell mobilization.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation.Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.
P2860
Q27692619-58B5B505-07E4-4B8F-8DEF-A2E4A0CBEA1EQ33411277-0D6771ED-93FC-43A5-B703-D98C42A9C0C3Q34114055-B58BD530-BDD8-432A-BE82-4F1E462304DEQ34762492-94614187-0328-4EE4-9054-34903C50CD2DQ35475882-C45C1E06-9992-4542-80D0-8743A98EDC3CQ36445393-5BC72098-8660-4105-8450-4A09676584BFQ37486616-E2793F20-36A1-47C2-A468-D6CA64683D66Q37649251-BB7D95AB-2A79-4A8A-9C99-BB472F7499A6Q37653639-29426F1A-097D-4482-A0BC-A092B0BE7905Q37707195-658FC240-305D-4E40-947F-64CCEB18FFCEQ37785509-B05B6F80-C74B-44CB-BB95-8D06E745FF78Q37909447-EFC1B295-5071-4B67-A403-69EE3888E7DBQ37921284-33D6D650-96BB-4D02-BAB8-4EA4EFE673C1Q37923309-C53F59EF-3C9E-47EB-A782-193835541FC9Q38077807-7E7B92CA-AC6A-464B-981A-4536CD82FBCCQ38183225-0D035728-C594-4FB9-B166-69162D9CB228Q38771080-6C7B621F-6608-4FA1-AD9C-0BD0794673BFQ38859426-6833C819-77D5-41BB-A7B8-00EEEFE0698CQ38880504-E13E9140-33A5-49C0-B767-5478803EEE3BQ39022841-D0C766F4-BFCA-4DEB-A9BC-92DED68D9BC2Q39724267-A7506A51-00E3-49D1-A110-D2FD7D8C6CA3Q41267193-8ECC5088-F0CC-49F7-A800-72D1E70B8AC5Q42204448-C98B1E0B-A99A-4B7E-9A7F-73AC4A7F4835Q44256421-11F0CF33-BB6E-4527-BEAD-052953BA28DCQ44736591-4E28AAB5-229B-4441-A345-2A0A518B221AQ45513822-C5D26705-4C04-4F43-A50B-965E0671232DQ45892382-C09FC5B3-2FEC-4586-B586-F09894412DF6Q46047228-8C857A82-468B-4564-9CE9-B8D6DD0426C5Q51385709-7509E835-2309-4589-B511-41AC82512B5EQ51405815-D2861B69-E48D-4D94-83BE-8CB73D3B63B6Q51680781-2501C390-349A-4449-BAD9-95C243879674Q51705517-BD271829-EED2-4203-8732-5CE9F36FEA52Q55094338-59E9735A-0462-47D8-9558-827CDC8CEDFE
P2860
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Treatment with plerixafor in n ...... he heavily pretreated patient.
@en
Treatment with plerixafor in n ...... he heavily pretreated patient.
@nl
type
label
Treatment with plerixafor in n ...... he heavily pretreated patient.
@en
Treatment with plerixafor in n ...... he heavily pretreated patient.
@nl
prefLabel
Treatment with plerixafor in n ...... he heavily pretreated patient.
@en
Treatment with plerixafor in n ...... he heavily pretreated patient.
@nl
P2093
P1476
Treatment with plerixafor in n ...... he heavily pretreated patient.
@en
P2093
Daniel Weisdorf
Gary Calandra
Ivana Micallef
Karin Badel
Margarida Magalhaes-Silverman
Mary Territo
Patrick Stiff
Philip McCarthy
P304
P356
10.1016/J.BBMT.2008.11.028
P577
2009-02-01T00:00:00Z